Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
Vertex Pharmaceuticals(VRTX) stock is priced at $462.90, giving the company a market capitalization of 117.44B. It carries a P/E multiple of 32.62.
During the trading session on 2025-12-27, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $463.65 and a low of $460.86. At a current price of $462.90, the stock is +0.4% higher than the low and still -0.2% under the high.
Trading volume for Vertex Pharmaceuticals(VRTX) stock has reached 375.32K, versus its average volume of 1.46M.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $519.68 and a low of $362.50.
VRTX News
Key Points Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it’s been on the rise. This other biotech has prov...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Twi...
Vertex Pharmaceuticals (VRTX) just delivered a busy update, with encouraging pediatric CASGEVY data, progress toward global filings, and an FDA Breakthrough The...
Analyst ratings
61%
of 36 ratingsMore VRTX News
Key Points CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has d...
If you are wondering whether Vertex Pharmaceuticals still offers good value after its big run, or if you would be buying in too late, you are in the right place...
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Vertex Pharmaceuticals and keeping the price target at $530.00. Claim 50% Off TipRanks Premiu...